White Paper
CertisAI Predictive Oncology Intelligence™ for Early Drug Development
AI‑Driven Efficacy Forecasts
Leverage tumor gene‑expression signatures to predict single‑agent and combination therapy responses before any bench work.
Instant Cancer‑Type Insights
Tap into 12 pre‑trained, indication‑specific models (from lung to skin cancer) or fine‑tune a custom model for your novel compound.
Comprehensive In Silico Library
Screen 2,200+ FDA‑approved drugs and over 1.9 billion potential combinations to pinpoint your highest‑value candidates.
Biomarker & Model Selection
Identify predictive gene signatures, optimal PDX/CCLE models, and companion‑diagnostic opportunities early in development.
Faster Leaner Development
Reduce costs, accelerate go/no‑go decisions, and minimize animal use with data‑driven guidance every step of the way.
Your Translational Partner
Certis Oncology Solutions is an AI-enabled translational science company dedicated to realizing the promise of precision oncology. At the core of the company’s platform is CertisAI™, a patented machine-learning system designed to model the relationships between drug chemistry and tumor biology.
By integrating computational modeling with functional testing in clinically relevant patient-derived tumor models, Certis generates Oncology Intelligence®—highly predictive therapeutic response data that helps pharmaceutical companies select better drug candidates, design smarter development strategies, and improve the probability of clinical success.